WINDLAS Stock Overview
Windlas Biotech Limited, a contract development and manufacturing organization (CDMO), manufactures and trades in pharmaceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Windlas Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹549.30 |
| 52 Week High | ₹590.85 |
| 52 Week Low | ₹249.25 |
| Beta | 0.49 |
| 1 Month Change | 5.92% |
| 3 Month Change | 13.36% |
| 1 Year Change | 118.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 34.91% |
Recent News & Updates
Recent updates
Is Now The Time To Put Windlas Biotech (NSE:WINDLAS) On Your Watchlist?
Nov 03
Windlas Biotech (NSE:WINDLAS) Is Increasing Its Dividend To ₹4.00
Aug 20Windlas Biotech (NSE:WINDLAS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
May 23Windlas Biotech Limited's (NSE:WINDLAS) Shares Lagging The Market But So Is The Business
Apr 07Shareholder Returns
| WINDLAS | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 5.8% | 2.7% | 2.8% |
| 1Y | 118.7% | 17.9% | 46.6% |
Return vs Industry: WINDLAS exceeded the Indian Life Sciences industry which returned 18.5% over the past year.
Return vs Market: WINDLAS exceeded the Indian Market which returned 46.4% over the past year.
Price Volatility
| WINDLAS volatility | |
|---|---|
| WINDLAS Average Weekly Movement | 7.9% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: WINDLAS has not had significant price volatility in the past 3 months.
Volatility Over Time: WINDLAS's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,049 | Komal Gupta | windlas.com |
Windlas Biotech Limited, a contract development and manufacturing organization (CDMO), manufactures and trades in pharmaceutical products in India and internationally. The company offers CDMO services, including product discovery, product development, licensing, and commercial manufacturing of generic products. It manufactures nutraceutical supplement products.
Windlas Biotech Limited Fundamentals Summary
| WINDLAS fundamental statistics | |
|---|---|
| Market cap | ₹11.42b |
| Earnings (TTM) | ₹526.38m |
| Revenue (TTM) | ₹6.00b |
21.7x
P/E Ratio1.9x
P/S RatioIs WINDLAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WINDLAS income statement (TTM) | |
|---|---|
| Revenue | ₹6.00b |
| Cost of Revenue | ₹3.82b |
| Gross Profit | ₹2.18b |
| Other Expenses | ₹1.66b |
| Earnings | ₹526.38m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 25.31 |
| Gross Margin | 36.37% |
| Net Profit Margin | 8.77% |
| Debt/Equity Ratio | 1.5% |
How did WINDLAS perform over the long term?
See historical performance and comparison